ethyl (1R,2S,4S,5R,6S)-5-[(6-chloro-5-nitro-2-propylsulfanylpyrimidin-4-yl)amino]-8,8-dimethyl-7,9-dioxatricyclo[4.3.0.02,4]nonane-2-carboxylate | 1423769-43-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl (1R,2S,4S,5R,6S)-5-[(6-chloro-5-nitro-2-propylsulfanylpyrimidin-4-yl)amino]-8,8-dimethyl-7,9-dioxatricyclo[4.3.0.02,4]nonane-2-carboxylate
• CAS: 1423769-43-0
• 化学式: C₁₉H₂₅ClN₄O₆S
• 分子量: 472.95
• InChiKey: PVOUQGMUCFDHGB-QNDPNIOESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  154
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  ethyl (1R,2S,4S,5R,6S)-5-[(6-chloro-5-nitro-2-propylsulfanylpyrimidin-4-yl)amino]-8,8-dimethyl-7,9-dioxatricyclo[4.3.0.02,4]nonane-2-carboxylate 在 铁粉 、 溶剂黄146 、 三乙胺 、 sodium nitrite 作用下， 以 水 、 溶剂黄146 、 乙腈 为溶剂， 生成
  参考文献：
  名称：

  Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists

  摘要：

  In this Letter we describe SAR investigation on the cyclopentyl-triazolol-pyrimidine scaffold in pursuit of new oral P2Y(12) inhibitors. Different synthetic routes were developed for variations at the cyclopentyl core. Optimization finally led to compound 2d which was advanced into preclinical development based on better potency and safety profile in comparison to ticagrelor. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.11.055
• 作为产物：
  描述：

  乙基(1S,2R,3S,4S,5S)-2,3-O-(异亚丙基)-4-羟基双环[3.1.0]己烷羧酸酯 在 偶氮二甲酸二异丙酯 、 三乙胺 、 三苯基膦 、 肼 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 ethyl (1R,2S,4S,5R,6S)-5-[(6-chloro-5-nitro-2-propylsulfanylpyrimidin-4-yl)amino]-8,8-dimethyl-7,9-dioxatricyclo[4.3.0.02,4]nonane-2-carboxylate
  参考文献：
  名称：

  Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists

  摘要：

  In this Letter we describe SAR investigation on the cyclopentyl-triazolol-pyrimidine scaffold in pursuit of new oral P2Y(12) inhibitors. Different synthetic routes were developed for variations at the cyclopentyl core. Optimization finally led to compound 2d which was advanced into preclinical development based on better potency and safety profile in comparison to ticagrelor. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.11.055